PresentedBy:MylesMurray,ManagingDirector&CEO

Toimprovepatientoutcomesbymakingeverybreathcountandtobecometheindustryleaderby2020

OurVision

Supportedby theEuropeanUnion'sHorizon2020researchandinnovationprogrammeundergrantagreementNo711269

NovelTechnologyatthecoreAbrandnewapproachtoRespiratoryEffortMonitoring-asignificantengineeringchallenge

Measuringthemostsensitiveindicatortowell-beingBreathing:RespiratoryEffortisatotalsystemindicatorofwellnessofferingupto48hoursearlyindicationofsickness

Ongoingresearch&developmentintopreventativemonitoring&diagnostictechnologiesMakingeverybreathcountbydevelopingrealtimebreathbybreathmonitoring- atrueindustryleaderinthisfield

PMDSolutions

Ongoingexcellenceinclinicalandappliedresearch

Constantclinicalinvestigationtoprovetheeffectivenessofourtechnology

Globalfocuswithaninternationalpresence

Genuineconcernoverpatient’soutcomeinacutecaretogetherwithinternationalpartners

• Peopleareliving longer• COPD(respiratorydiseases)3rd biggestkiller by2030• Emergency andUrgentCareunderseverepressure• Disease statessuchassleep disordersgoingundiagnosed forupto2

yearspostsymptomsbeing recognised

• Healthier living:MoreyearsandBetterLife• Betteracutecaremanagement (LowerEventRate)• Reducingpreventable comorbidities thusimprovehealthcare

economics +QualityofLife

Preventativemonitoringiskey,earlydetectionisvital

ImpacttoEuropeanSociety

Establishrecognitionasindustryleaders

Growthemarket Scale

ChangingtheStatusQuo

• OTS tablet device• Android• Disposable single use sensor• Respiratory rate trend

monitoring• Continuous monitoring

4 days battery

In-patient RR monitor

• OTS mobile phone• Android• Zero patient engagement

needed• Cloud processing + report

generation

+

Presentlybothclinical applications usethesamedevice

Respirasense

Home Sleep Test

All comm’s are BT

Platform- 2applications:1product

RS Sleep Screener

RespiraSense

Totriggertheearliestintervention

Andimprovedhealthcareeconomics

Leadingtobetterpatientoutcomes

Thefirstsignofabnormalbreathing

ContinuousrateMonitoringallows;

WhyisRRimportant?

RespiraSense

Costing€18,000perevent

RespiraSensecangive>80%ROIbyimpacting1in20patients

Upto7additionalbeddays

7%GeneralWard&11%Post-op

IncidenceofRespiratoryCompromisetoIncreaseby31%by2020

StatusQuoBandsslip,leadingtore-testsBandsareuncomfortable

PMDischangingtheStatusQuo• Bandsreplacedwithsimple

adhesiveRSsensor• Chest&gutmeasurements

+Position+Activity

Consumerapplicationpotentialforhomescreening

RSSleepScreener

Toincreasetheirpatientcoverage

Toidentifyandservemoreapnoea suffers

Withminimumincreases inresources

Canenablesleepserviceproviders

Asimpleandaccurateeventscreener;

WhyScreen?

Today,avalidatedtechnology

2016Efficacywithallproducts

2017EvaluationofEconomicImpacttoHealthcare

ClinicalEvidence

InternationalTeam- Objectivesa.)EstablishCommercial Pathwayb.)Increase UserBasec.)RetainExisting UserBased.)NetworktheGlobalUserBase

MarketPresence

Application1- buildproposition: InvestmentBusinessPlan,Ifwegotitwhatwouldweactuallywanttodo

Application2– refineExcellence andImpactwithlatestcompanyupdates

Application3– Refineandrefine implementationincluding partners forskill gaps,therightbudget,therightAmbition

1Year

3Attempts

1st inEurope

H2020– OnlyOpportunity forSMEFunding

Bemindful,projectsarereviewedbypeopleSpeakthe language

Tell thestory

Excite themProveit

H2020– AnElementofFundingStrategy

Bigambition&clearplantoexecute

LeveragetoraiseGrowthCapitalfromVCfunds

H2020,oneoptionofmany

Therightvalidatedproposition

PMDfundedbyAngles&H2020

Thankyoufortheopportunity topresentouroffering

MylesMurrayManagingDirector&CEOmyles@pmd-solutions.comBishopstownHouse|ModelFarmRoad|Co.Cork|Ireland

SupportedbytheEuropeanUnion'sHorizon2020research andinnovationprogrammeundergrantagreement No711269